AKBA vs DHR · rev $102.7M vs P/E 39, rev $6.26B
Akebia Ther (AKBA) versus Danaher Corporation (DHR) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
Danaher Corporation (DHR) is a diagnostics & research company listed on US.
Latest reported AKBA revenue for 2026-06-30 was $102.7M. Net income was -$18.0M. Revenue was up 91.8% from 2026-03-31 to 2026-06-30. AKBA currently screens at market cap $260.1M.
Latest reported DHR revenue for 2026-06-26 was $6.26B. Net income was $870.0M. Revenue was up 5.3% from 2026-03-27 to 2026-06-26. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
AKBA currently screens at market cap $260.1M. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
Not investment advice. Open the AKBA and DHR stock pages for the full models.
Not investment advice.